Starton Holdings

  IPO Overview Phase 2 oncology drug developer Starton Holdings files and sets terms for a $40 million IPO Starton Holdings, a Phase 2 developer of controlled release formulations for an approved cancer drug, filed on Thursday with the SEC... Read more